311 related articles for article (PubMed ID: 38269619)
1. Immune cells in the B-cell lymphoma microenvironment: From basic research to clinical applications.
Zhang W; Liu M; Li W; Song Y
Chin Med J (Engl); 2024 Apr; 137(7):776-790. PubMed ID: 38269619
[TBL] [Abstract][Full Text] [Related]
2. Targeting the tumor microenvironment in B-cell lymphoma: challenges and opportunities.
Liu Y; Zhou X; Wang X
J Hematol Oncol; 2021 Aug; 14(1):125. PubMed ID: 34404434
[TBL] [Abstract][Full Text] [Related]
3. Tumor microenvironment and CAR-T cell immunotherapy in B-cell lymphoma.
Cai F; Zhang J; Gao H; Shen H
Eur J Haematol; 2024 Feb; 112(2):223-235. PubMed ID: 37706523
[TBL] [Abstract][Full Text] [Related]
4. The tumor microenvironment of lymphomas: Insights into the potential role and modes of actions of checkpoint inhibitors.
Menter T; Tzankov A; Dirnhofer S
Hematol Oncol; 2021 Feb; 39(1):3-10. PubMed ID: 33105031
[TBL] [Abstract][Full Text] [Related]
5. Unleashing Natural Killer Cells in the Tumor Microenvironment-The Next Generation of Immunotherapy?
Ben-Shmuel A; Biber G; Barda-Saad M
Front Immunol; 2020; 11():275. PubMed ID: 32153582
[TBL] [Abstract][Full Text] [Related]
6. Befriending the Hostile Tumor Microenvironment in CAR T-Cell Therapy.
Lindo L; Wilkinson LH; Hay KA
Front Immunol; 2020; 11():618387. PubMed ID: 33643299
[TBL] [Abstract][Full Text] [Related]
7. Targeting immune checkpoints in hematological malignancies.
Salik B; Smyth MJ; Nakamura K
J Hematol Oncol; 2020 Aug; 13(1):111. PubMed ID: 32787882
[TBL] [Abstract][Full Text] [Related]
8. The Role of Extracellular Vesicles in the Pathogenesis of Hematological Malignancies: Interaction with Tumor Microenvironment; a Potential Biomarker and Targeted Therapy.
Das K; Mukherjee T; Shankar P
Biomolecules; 2023 May; 13(6):. PubMed ID: 37371477
[TBL] [Abstract][Full Text] [Related]
9. TIGIT is Frequently Expressed in the Tumor Microenvironment of Select Lymphomas: Implications for Targeted Therapy.
Libert D; Zhao S; Younes S; Mosquera AP; Bharadwaj S; Ferreira C; Natkunam Y
Am J Surg Pathol; 2024 Mar; 48(3):337-352. PubMed ID: 38148663
[TBL] [Abstract][Full Text] [Related]
10. Combining precision oncology and immunotherapy by targeting the MALT1 protease.
Mempel TR; Krappmann D
J Immunother Cancer; 2022 Oct; 10(10):. PubMed ID: 36270731
[TBL] [Abstract][Full Text] [Related]
11. Broadening the horizon: potential applications of CAR-T cells beyond current indications.
Karsten H; Matrisch L; Cichutek S; Fiedler W; Alsdorf W; Block A
Front Immunol; 2023; 14():1285406. PubMed ID: 38090582
[TBL] [Abstract][Full Text] [Related]
12. Cell cross talk within the lymphoma tumor microenvironment: follicular lymphoma as a paradigm.
Laurent C; Dietrich S; Tarte K
Blood; 2024 Mar; 143(12):1080-1090. PubMed ID: 38096368
[TBL] [Abstract][Full Text] [Related]
13. CCL8 as a promising prognostic factor in diffuse large B-cell lymphoma
Lou X; Zhao K; Xu J; Shuai L; Niu H; Cao Z; Wang J; Zhang Y
Front Immunol; 2022; 13():950213. PubMed ID: 36072582
[TBL] [Abstract][Full Text] [Related]
14. Targeting the immune microenvironment for ovarian cancer therapy.
Blanc-Durand F; Clemence Wei Xian L; Tan DSP
Front Immunol; 2023; 14():1328651. PubMed ID: 38164130
[TBL] [Abstract][Full Text] [Related]
15. Ferroptosis and tumor immunity: In perspective of the major cell components in the tumor microenvironment.
Zhu W; Liu X; Yang L; He Q; Huang D; Tan X
Eur J Pharmacol; 2023 Dec; 961():176124. PubMed ID: 37925133
[TBL] [Abstract][Full Text] [Related]
16. Insights into the tumor microenvironment of B cell lymphoma.
Ng WL; Ansell SM; Mondello P
J Exp Clin Cancer Res; 2022 Dec; 41(1):362. PubMed ID: 36578079
[TBL] [Abstract][Full Text] [Related]
17. The ectonucleotidases CD39 and CD73 on T cells: The new pillar of hematological malignancy.
Jiang X; Wu X; Xiao Y; Wang P; Zheng J; Wu X; Jin Z
Front Immunol; 2023; 14():1110325. PubMed ID: 36776866
[TBL] [Abstract][Full Text] [Related]
18. The role of innate immune cells in the tumor microenvironment and research progress in anti-tumor therapy.
Lu C; Liu Y; Ali NM; Zhang B; Cui X
Front Immunol; 2022; 13():1039260. PubMed ID: 36741415
[TBL] [Abstract][Full Text] [Related]
19. Epstein-Barr Virus-Positive Lymphomas Exploit Ectonucleotidase Activity To Limit Immune Responses and Prevent Cell Death.
Lange PT; Damania B
mBio; 2023 Apr; 14(2):e0345922. PubMed ID: 36786572
[TBL] [Abstract][Full Text] [Related]
20. Vγ9Vδ2 T-cell immunotherapy in blood cancers: ready for prime time?
Giannotta C; Autino F; Massaia M
Front Immunol; 2023; 14():1167443. PubMed ID: 37143664
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
